NEW YORK (GenomeWeb News) – Agilent said after the close of the market on Wednesday that its Fiscal Year 2014 second quarter revenues were flat year over year, while its Life Sciences and Diagnostic revenues increased 1 percent.

For the three months ended April 30, Agilent reported total revenues of $1.73 billion, unchanged from a year ago and even with the consensus analyst estimate. Orders in the quarter were up to $1.81 billion from $1.69 billion a year ago.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A former Synthetic Genomics attorney alleges that the firm discriminated against her and other female employees, according to the San Diego Union-Tribune.

Due to privacy and lab certification questions, the planned giveaway of Orig3n testing kits at a Baltimore Ravens game was suspended.

Alnylam reports positive results from its phase 3 clinical trial of an RNAi-based drug, according to Stat News.

In Cell this week: adult mesenchymal cell populations in mouse lung, genetic diversity in HPV16 and cancer risk protection, and more.